In some ALK-negative cases, alternative genetic alterations such as RET, ROS1, or NTRK3 fusions may be present.[28,29] These fusions may serve as oncogenic drivers in the pathogenesis of IMT. This evidence concerns the gene RET and inflammatory myofibroblastic tumor.